1. Home
  2. DSY vs SCYX Comparison

DSY vs SCYX Comparison

Compare DSY & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DSY

Big Tree Cloud Holdings Limited Ordinary Shares

HOLD

Current Price

$3.11

Market Cap

28.5M

Sector

N/A

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.74

Market Cap

32.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DSY
SCYX
Founded
2020
1999
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.5M
32.6M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
DSY
SCYX
Price
$3.11
$0.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
105.9K
315.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
$170.77
Revenue Next Year
N/A
$286.38
P/E Ratio
$16.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.17
$0.57
52 Week High
$4.01
$1.29

Technical Indicators

Market Signals
Indicator
DSY
SCYX
Relative Strength Index (RSI) 79.20 48.76
Support Level $0.33 $0.69
Resistance Level $4.01 $0.87
Average True Range (ATR) 0.19 0.05
MACD 0.26 -0.01
Stochastic Oscillator 75.52 25.73

Price Performance

Historical Comparison
DSY
SCYX

About DSY Big Tree Cloud Holdings Limited Ordinary Shares

Big Tree Cloud Holdings Ltd is a consumer-oriented, mission-driven, and technology-empowered company engaged in the development, production, distribution, and sales of personal care products and other consumer goods. Operating under a consumer-to-manufacturer and merchant (C2M) model, the company integrates online and offline operations to enhance customer engagement, product innovation, and marketing efficiency. Specializing in feminine hygiene products such as sterilized feminine pads, menstrual pants, and related items, Big Tree Cloud leverages its platform to consolidate resources within China's personal care industry while building a consumer community that provides direct feedback and product insights.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: